Figure 4
From: JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients
Memory/Naïve T lymphocyte subsets. Relative proportions of VP-1 stimulated CD8+naïve (CCR7+CD45RA+), central memory (CM: CCR7+CD45RA-), effector memory (EM: CCR7-CD45RA-), and terminally differentiated (TD: CCR7-CD45RA+) T lymphocytes in Multiple Sclerosis patients undergoing natalizumab. Samples were tested at baseline (PRE), at the time of JCV DNA isolation in blood (POS), and after 24 months of therapy (POST).
